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Abstract: ‘Desymmetrization’ of trans-1,2-diaminocyclohexane by treatment with α,ω-dihalogenated
alkylation reagents leads to mono-NH2 derivatives (‘primary-tertiary diamines’). Upon reaction with
formaldehyde, these products formed monomeric formaldimines. Subsequently, reactions of the
formaldimines with α-hydroxyiminoketones led to the corresponding 2-unsubstituted imidazole
N-oxide derivatives, which were used here as new substrates for the in situ generation of chiral
imidazol-2-ylidenes. Upon O-selective benzylation, new chiral imidazolium salts were obtained,
which were deprotonated by treatment with triethylamine in the presence of elemental sulfur.
Under these conditions, the intermediate imidazol-2-ylidenes were trapped by elemental sulfur,
yielding the corresponding chiral non-enolizable imidazole-2-thiones in good yields. Analogous
reaction sequences, starting with imidazole N-oxides derived from enantiopure primary amines,
amino alcohols, and amino acids, leading to the corresponding 3-alkoxyimidazole-2-thiones were
also studied.
Keywords: carbene sulfurization; chiral compounds; chiral nucleophilic carbenes; imidazoleN-oxides;
imidazole-2-thiones; N-alkoxyimidazolium salts
1. Introduction
Since 1991, after the isolation of the first stable 1,3-di(adamantyl)imidazol-2-ylidene [1], there
has been a wealth of both structural studies and practical applications of nucleophilic N-heterocyclic
carbenes (NHCs) [2,3]. At the same time, there is continuing demand for catalysts and ligands
for asymmetric synthesis [4]. Chiral NHCs are particularly suitable for such applications, and
the elaboration of methods for the preparation of their precursors and subsequent applications in
asymmetric synthesis are intensively pursued [5–8]. One efficient method for the preparation of chiral
Molecules 2019, 24, 4398; doi:10.3390/molecules24234398 www.mdpi.com/journal/molecules
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NHCs is the introduction of a chiral fragment attached to the N-atom located within the heterocyclic
skeleton (chiral N-substituents).
It is therefore natural that one of the most important motifs in the structure of catalysts and
ligands for asymmetric catalysis derives from easily available and inexpensive enantiomerically pure
(R,R)-trans-1,2-diaminocylohexane (trans-DACH, Scheme 1) [9,10]. Numerous derivatives of this
exceptional diamine have been synthesized via functionalization of only one or both amino groups.
In recent years, much attention has been paid to so-called bifunctional catalysts, which are prepared
by modifications of the amino groups. Derivatives of type 1 with a cyclic amine motif are promising
building blocks for the synthesis of new bifunctional catalysts [11,12] and are important synthons for
the preparation of some bioactive compounds [13–17]. An efficient method for the ‘desymmetrization’
of DACH, reported only in recent years, comprises two-fold N,N-alkylation of only one NH2 group
using α,ω-dihaloalkylating reagents as shown in Scheme 1 [12].
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Sche e 1. trans-1,2-dia inocyclohexane (DACH) and its ‘desy etrized’ derivatives 1 (Reproduced
with permission from [12]).
Along with trans-DACH, another primary amine widely explored in asymmetric synthesis is
α-methylbenzylamine (α-MBA), but to date, reports on its application in the synthesis of chiral NHCs
are limited [6]. Similarly, chiral β-amino alcohols and amino esters have scarcely been explored.
Selected representatives of these two classes of compounds will also be involved in this study.
It is well established that the most efficient and preparatively useful method for the in situ
generation of imidazol-2-ylidenes 3 comprises the deprotonation of the corresponding imidazolium
salts of type 2 by treatment with a base (Scheme 2) [2,3].
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In our earlier publications, we described an efficient method for the synthesis of enantiomerically
pure bis- and mono-imidazole N-oxides derived either from trans-1,2-diaminocyclohexane [18,19],
α-methylbenzylamine [20], β-amino alcohols [21], and amino acid esters [22]. In another study,
we demonstrated that 2-unsubstituted imidazole N-oxides including some chiral derivatives can
be O-alkylated by treatment with alkyl bromides [23]. However, these 1-alkoxyimidazolium salts
have never been used for the generation of N-alkoxy-substituted imidazol-2-ylidenes of type 3. In
a very recent publication, we reported the synthesis of non-symmetric imidazolium salts prepared
in a multistep synthesis starting with adamantyloxyamine [24]. In a test experiment, a symmetric
1,3-di(adamantyloxy)imidazolium salt was converted into the corresponding imidazole-2-thione
derivative via an intermediate NHC. Prompted by these results, we decided to synthesize a series of
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new chiral 1-alkoxyimidazolium salts derived from ‘desymmetrized’ trans-1,2-diaminocylohexane
derivatives of type 1, which can subsequently be used as precursors of chiral NHCs. The study was
extended by the involvement of α-methylbenzylamine as well as selected amino alcohols and amino
acid derivatives.
2. Results and Discussion
In contrast to DACH, which reacts with two equivalents of formaldehyde forming a dimeric
product identified as a tetraazaeicosane derivative [25], all ‘primary-tertiary’ diamines 1a–d reacted
with formaldehyde yielded the expected formaldimines 4a–d as solid products (Scheme 3). In
the solid state they exist as hexahydro-1,3,5-triazines (trimers), which in polar, aprotic solvents
undergo almost total dissociation forming the monomeric imines. Similar observations were made
for cyclohexylformaldimine [26]. For example, formaldimine 4b dissolved in CDCl3 dissociates with
t1/2 of ca. 30 s at 298 K. On the other hand, the same imine observed in the C6D6 solution exists as
an equilibrium mixture of trimeric and monomeric forms in a ratio of ca. 2.5:1. The structures of
formaldimines 4 were confirmed by 1H and 13C-NMR spectra in CDCl3. For example, in the 1H-NMR
spectrum of 4b, the characteristic AB-system of the monomeric form located at 7.13 and 7.28 ppm with
J = 18 Hz was attributed to the N=CH2 group. In the 13C-NMR spectrum, the signal of this group
appeared at 151.0 ppm, and similar data were found for all formaldimines 4. However, in all samples,
the presence of trimeric forms interfered with the integration of signals. The presence of trimers was
revealed by signals of the CH2 groups located at 3.80–4.00 ppm. The products were unstable in solution
and underwent gradual decomposition over a period of weeks during storage at room temperature.
The molecular formulae of the stable, crystalline samples were confirmed by elemental analysis.
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In the case of 4e derived from (S)-α-methylbenzylamine ((S)-α-MBA), rapid trimerization led to
hexahydro-1,3,5-triazine 4′e (Scheme 4) in the course of its synthesis, and after isolation, it could be
used for further transformations only in this form [20]. An analogous tendency for trimerization was
also observed for 4f–h used in the study.
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In contrast, the alkoxyformaldimine 4i derived from (S)-α-methylbenzyloxyamine (α-MBOA) [27]
exists in CDCl3 solution in monomeric form, and in that case, no tendency to undergo trimerization was
observed even after three days at room temperature. Moreover, a similar behavior was observed in the
case of benzyloxyformaldimine (4j) prepared from benzyloxyamine (BOA) [28] and formaldehyde in
the course of the present study. Apparently, the presence of an alkoxy moiety reduces the electrophilicity
of the =CH2 unit and thereby formation of the trimeric forms is substantially disfavored.
Enantiomerically pure, (R,R)-configured 2-unsubstituted imidazole N-oxides 6 used in this
study as the key building blocks were prepared from enantiopure formaldimines 4, derived from the
corresponding amines 1, andα-hydroxyiminoketones 5a,b in glacial acetic acid at room temperature [24].
In the case of 4b, along with the (R,R)-configured stereoisomer, the (S,S)-enantiomer was also involved
in the study (Scheme 5 and Table 1).
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R 1 (%) 1
( ,R) a Me 62
(R,R) a (CH2)4 Ph b 93 b 70
(R,R) b (CH2)5 Me c 90 c 60
(R,R) b (CH2)5 Ph d 65 d 82
(S,S) b (CH2)5 Me c 95 c 47
( ,S) b ( 2)5 Ph d 83 d 62
(R,R) c ( )6 Me e 78 e 42
(R,R) c (CH2)6 Ph f 89 f 70
(R,R) d (CH2)2O(CH2)2 Me g 86 g 67
(R,R) d (CH2)2O(CH2)2 Ph h 66 h 81
1 Yield of isolated compounds.
Reactions of 4 with α-hydroxyiminoketones 5 leading to imidazole N-oxides 6 were performed
at room temperature in glacial acetic acid. After isolation, the products were identified by
spectroscopic methods, and the most characteristic signal of HC(2) of the imidazole ring in the
1H-NMR spectra appeared at ca. 8 ppm. Products 6 were alkylated with an equimolar amount of
benzyl bromide in CH2Cl2 solution at room temperature. Due to the observed slow decomposition,
the (N-benzyloxy)imidazolium salts 7 were used for the next reaction step without further purification.
In the case of the azepane derivative 7e, the structure of the crude product was confirmed by 1H-NMR
spectroscopy. The characteristic HC(2)-signal was significantly shifted toward the lower field and
appeared at 11.35 ppm. In addition, chemoselective O-benzylation was confirmed by the appearance
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of only one AB-system (5.67 and 5.72 ppm, J = 12.0 Hz) of the OCH2Ph group. Thus, competitive
N-benzylation could be ruled out.
The obtained crude imidazolium salts 7 were used as precursors of chiral imidazol-2-ylidenes
8 (Scheme 6). Their intermediacy was proven with known trapping reactions with elemental
sulfur [24,29,30] leading to non-enolizable imidazole-2-thiones. The deprotonation of 7 was easily
achieved by treatment with triethylamine in pyridine. In the presence of elemental sulfur, the in
situ generated NHCs 8 exclusively reacted with the desired imidazole-2-thiones 9 (Scheme 6 and
Table 1). Their structures were confirmed by spectroscopic data with the most characteristic signal
in the 13C-NMR spectra being the C(2)=S group resonating between 156 and 162 ppm. The obtained
imidazole-2-thiones 9a–h were shown to be optically active compounds. The optical rotation for all
these products was determined in CHCl3 solutions and no racemization under the reaction conditions
is expected.
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The inspection of the 1H-NMR spectra of 9 in CDCl3 solution at room temperature evidenced
complex signal patterns. It is likely that there are equilibria of different rotamers and/or conformers
existing in these solutions. To acquire more information, the 1H-NMR spectra of analytically pure
(R,R)-9b were recorded at different temperatures in a 1,1,2,2-tetrachloroethane solution. The spectrum
at 294 K showed a set of broadened signals in the region of 4.2–4.8 ppm attributed to the PhCH2O
fragment. In addition, two broad signals of H(C1) and HC(2) of the cyclohexane ring were found at 2.8
and 3.1 ppm. In the spectrum measured at 334 K, the benzylic region revealed one broad signal at
4.6 ppm and the signals of two distinct cyclohexane H-atoms were shifted high-field and overlap with
the α-H-atoms of the pyrrolidine ring. This observation supports our assumption of the presence of a
dynamic equilibrium of different conformers of (R,R)-9b. An analogous explanation is valid for all
spectra of 9 bearing two Ph groups at C(4) and C(5) of the imidazole ring.
In extension of the studies performed with ‘desymmetrized’ trans-DACH derivatives, analogous
experiments were performed starting with enantiomerically pure functionalized primary amines.
Thus, the corresponding formaldimines 4f–h (Scheme 4) were converted into imidazole N-oxides
10a–c by reaction with the α-hydroxyiminoketone 5a under standard conditions (see Experimental
Section). In addition, enantiopure 10d, readily available by aminolysis of the corresponding ester
with (R)-α-MBA [22] was used. The obtained imidazole N-oxides 10 were used for the preparation
of imidazolium salts 11a–d, which upon treatment with triethylamine in pyridine in the presence of
elemental sulfur gave the optically active imidazole-2-thiones 13a–d in good yields (Scheme 7). In
these reactions, optically active N-butoxyimidazol-2-ylidenes of type 12 were the in situ generated
reactive intermediates.
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Scheme 8. 3-Alkoxyimidazole-2-thiones 15a–d derived from (S)-α-methylbenzylamine. 
In that case, the less bulky (S)-α-methylbenzyl residue was placed at the N(1) atom. The 1H-
NMR spectrum of 15a reveals the presence of the expected AB system of the PhCH2O group at 5.45 
and 5.58 (J = 10 Hz) ppm. This result emphasizes the importance of the steric demand in the series of 
compounds 9 derived from bulky trans-1,2-diaminocyclohexane. 
3. Conclusions 
Enantiomerically pure desymmetrized derivatives of trans-1,2-diaminocyclohexane containing 
one free NH2 group (i.e., so called ‘primary-tertiary amines’) can be efficiently converted into 
c . t sis f tic ll cti - t i i l - -t i s .
In contrast to 9b,d,f, and g derived from (R,R)-trans-DACH, the 1H-NMR spectra of 13 clearly
indicated the presence of a single form in the solution. For example, the spectrum of compound 13b
showed only one multiplet for the CH2O unit located at 4.34–4.41 ppm, and two characteristic singlets
of the Me groups at C(4) and C(5) of the imidazole ring at 1.72 and 2.09 ppm, respectively. In the
13C-NMR spectrum, the signal of the C=S group appeared at 157.4 ppm.
In order to check whether steric hindrance is the reason for the existence of different conformers of 9,
four other compounds of that type (i.e., 15a–d derived from (S)-α-methylbenzylamine) were synthesized
following the multistep procedure presented in Schemes 6 and 7. The starting 2-unsubstituted imidazole
N-oxides 14a,b are known compounds [20]. Upon treatment with alkylating reagents (benzyl bromide
or n-pentyl bromide), they were converted into the corresponding imidazolium salts (Scheme 8). The
latter products without purification were treated with triethylamine in the presence of elemental sulfur,
yielding the desired 15a–d in good yields (66–81%).
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3. Conclusions 
Enantiomerically pure desymmetrized derivatives of trans-1,2-diaminocyclohexane containing 
one free NH2 group (i.e., so called ‘primary-tertiary amines’) can be efficiently converted into 
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In that case, the less bulky (S)-α-methylbenzyl residue was placed at the N(1) atom. The 1H-NMR
spectrum of 15a reveals the presence of the expected AB system of the PhCH2O group at 5.45 and
5.58 (J = 10 Hz) ppm. This result emphasizes the importance of the steric de and in the series of
co pounds 9 derived fro bulky trans-1,2-dia inocyclohexane.
3. Conclusions
Enantiomerically pure desymmetrized derivatives of trans-1,2-diaminocyclohexane containing one
free NH2 group (i.e., so called ‘primary-tertiary amines’) can be efficiently converted into corresponding
formaldimines. The initially obtained formaldimines were transformed into 2-unsubstituted
imidazole N-oxides, which upon treatment with benzyl bromide were selectively converted into
benzyloxyimidazolium salts. After deprotonation with triethylamine, the latter compounds generated
new types of chiral imidazol-2-ylidenes. Their appearance was evidenced by the trapping reaction
with elemental sulfur leading to chiral non-enolizable imidazole-2-thiones. The same procedure
applied to other optically active functionalized primary amines opens straightforward access for in
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situ generated nucleophilic carbenes derived from imidazole (imidazol-2-ylidenes) bearing an alkoxy
group. This little-known class of alkoxy-substituted optically active NHCs is of interest for potential
applications in asymmetric synthesis and in organometallic chemistry for the preparation of transition
metal complexes. The multistep synthesis of the optically active imidazole-2-thiones occurs with
preservation of the stereochemistry. In addition, many derivatives of chiral 1,2-diamines [13,15,31,32],
imidazolium salts [33–35] as well as numerous imidazole-2-thiones [36,37] display diverse biological
activities. Nevertheless, their alkoxy derivatives are practically unknown. For that reason, the new
types of ‘desymmetrized’ derivatives of trans-1,2-diaminocyclohexane and other optically active
primary amines reported in this work may also be of interest for medicinal chemistry.
4. Materials and Methods
4.1. General Information
Solvents and chemicals were purchased and used as received without further purification.
Products were purified by standard column chromatography on silica gel (230–400 mesh, Merck,
Kenilworth, NJ, USA). Unless stated otherwise, yields refer to analytically pure samples. NMR spectra
were recorded with a Bruker Avance III 600 MHz instrument (1H-NMR: 600 MHz; 13C-NMR: 151 MHz;
Bruker, Billerica, MA, USA). Chemical shifts are reported relative to solvent residual peaks (1H-NMR:
δ = 7.26 ppm [CHCl3]; 13C-NMR: δ = 77.0 ppm [CDCl3]). IR spectra were recorded with a FTIR NEXUS
spectrometer (as film or KBr pellets) or with a Cary 630 FTIR (Agilent Technologies, Santa Clara,
CA, USA) spectrometer, in neat. ESI-MS spectra were performed with a Varian 500-MS LC Ion Trap.
High-resolution mass spectrometry (HRMS) measurements were performed using Synapt G2-Si mass
spectrometer (Waters, Milford, MA, USA) equipped with an ESI source and quadrupole-Time-of-flight
mass analyzer. Elemental analyses were obtained with a Vario EL III (Elementar Analysensysteme
GmbH, Langenselbold, Germany) instrument. Optical rotations were determined with an Anton Paar
MCP 500 polarimeter (Anton Paar, Graz, Austria) at the temperatures indicated. Melting points were
determined in capillaries with a Stuart SMP30 apparatus with automatic temperature monitoring or
with a polarizing optical microscope (Opta-Tech, Warszawa, Poland), and are uncorrected.
4.2. Starting Materials
The ‘primary–tertiary’ amines 1 (i.e., compounds (R,R)-1a, (R,R)-1b, (S,S)-1b,
(R,R)-1c, and (R,R)-1d) were prepared from the respective, enantiopure diastereomers
of trans-1,2-diaminocyclohexane (trans-DACH), according to the literature procedure [12].
α-Hydroxyiminoketones 5 were prepared by nitrozation of ethyl methyl ketone in the case of
7a [38] and by oximation of dibenzoyl in the case of 7b [39] based on the published procedures.
α-Methylbenzyloxyamine (α-MBOA) [27] and benzyloxyamine (BOA) [40] were prepared based on
modified literature procedures. Formaldimines 4e [20], 4f [21], 4g [21], and 4h [22] were synthetized
from corresponding amino compounds and formaldehyde based on the published procedures.
4.3. Synthesis of Formaldimines 4
4.3.1. Reactions of ‘Primary-Tertiary’ Amines 1 with Formaldehyde—General Procedure
A solution of 5 mmol of the respective diamine 1 and 450 mg (15 mmol) of formaldehyde (used as
an aqueous solution) in 50 mL of benzene was heated in the Dean-Stark apparatus over 1.5 h. Next,
the solvent was evaporated and the crude products were obtained as colorless solids. Analytically
pure samples were obtained by recrystallization.
(R,R)-N-[2-(Pyrrolidin-1-yl)cyclohexyl]methanimine ((R,R)-4a): Yield 855 mg (95%). Colorless crystals
(diisopropyl ether). M.p. 97–98 ◦C. [α]25D = −135.30 (c 0.40, CHCl3). 1H-NMR (CDCl3): δ = 7.39 (d,
J = 17.2 Hz, 1H), 7.13 (d, J = 17.2 Hz, 1H), 2.93–2.97 (m, 1H), 2.66–2.71 (m, 1H), 2.52–2.62 (m, 4H),
1.86–1.91 (m, 1H), 1.72–1.77 (m, 1H), 1.60–1.69 (m, 4H), 1.52–1.58 (m, 2H), 1.23–1.30 (m, 3H), 1.12–1.20
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(m, 1H) ppm. 13C-NMR (CDCl3): δ = 151.1, 74.4, 63.4, 48.4, 34.0, 24.6, 24.2, 23.9, 23.5 ppm. IR: ν 2920
(vs), 2851 (s), 2801 (s), 1457 (m), 1384 (m), 1369 (m), 1183 (s), 1135 (vs), 997 (vs), 898 (m), 875 (m), 766
(m) cm−1. C11H20N2 (180.29): calcd. C 73.28, H 11.18, N 15.54; found C 73.27, H 11.15, N 15.60.
(R,R)-N-[2-(Piperidin-1-yl)cyclohexyl]methanimine ((R,R)-4b): Yield 756 mg (78%). Colorless crystals
(diethyl ether). M.p. 126–128 ◦C. [α]25D = −130.92 (c 0.40, CHCl3). 1H-NMR (CDCl3): δ = 7.28 (d, J = 17.2
Hz, 1H), 7.13 (d, J = 17.2 Hz, 1H), 2.93 (td, J = 9.9, 5.2 Hz, 1H), 2.45–2.62 (m, 3H), 2.29–2.37 (m, 2H),
1.8–11.86 (m, 1H), 1.72–1.79 (m, 1H), 1.58–1.69 (m, 3H), 1.44–1.51 (m, 2H), 1.30–1.40 (m, 4H), 1.10–1.25
(m, 3H) ppm. 13C-NMR (CDCl3): δ = 151.0, 72.4, 67.3, 49.6, 34.6, 26.6, 25.6, 25.1, 24.6, 23.6 ppm. IR: ν
2924 (vs), 2849 (s), 1450 (m), 1381 (m), 1360 (m), 1191 (s), 1127 (vs), 1114 (vs), 1004 (vs), 911 (m), 876 (m),
766 (m), 641 (m) cm–1. C12H22N2 (194.32): calcd. C 74.17, H 11.41, N 14.42; found C 74.17, H 11.38,
N 14.46.
(S,S)-N-[2-(Piperidin-1-yl)cyclohexyl]methanimine ((S,S)-4b): Yield 775 mg (80%). Colorless crystals
(diethyl ether). M.p. 125–127 ◦C. [α]25D = +140.97 (c 0.40, CHCl3). 1H-NMR (CDCl3): δ = 7.28 (d, J = 17.2
Hz, 1H), 7.14 (d, J = 17.2 Hz, 1H), 2.94 (td, J = 9.9, 5.3 Hz, 1H), 2.46–2.61 (m, 3H), 2.28–2.36 (m, 2H),
1.82–1.86 (m, 1H), 1.73–1.79 (m, 1H), 1.59–1.70 (m, 3H), 1.44–1.52 (m, 2H), 1.31–1.40 (m, 4H), 1.12–1.26
(m, 3H) ppm. 13C-NMR (CDCl3): δ = 151.1, 72.4, 67.3, 49.6, 34.6, 26.6, 25.6, 25.1, 24.6, 23.6 ppm. IR: ν
2924 (vs), 2849 (s), 1450 (m), 1381 (m), 1360 (m), 1191 (s), 1127 (vs), 1114 (vs), 1004 (vs), 911 (m), 876 (m),
641 (m) cm–1. C12H22N2 (194.32): calcd. C 74.17, H 11.41, N 14.42; found C 73.99, H 11.55, N 14.38.
(R,R)-N-[2-(Azepan-1-yl)cyclohexyl]methanimine ((R,R)-4c): Yield 969 mg (93%). Colorless crystals
(diisopropyl ether). M.p. 112–114 ◦C. [α]25D = –81.57 (c 0.40, CHCl3). 1H-NMR (CDCl3): δ = 7.32 (d,
J = 17.3 Hz, 1H), 7.13 (d, J = 17.3 Hz, 1H), 2.90 (td, J = 10.0, 5.0 Hz, 1H), 2.64–2.68 (m, 2H), 2.59–2.64
(m, 1H), 2.50–2.55 (m, 2H), 1.79–1.82 (m, 1H), 1.71–1.76 (m, 1H), 1.63–1.68 (m, 1H), 1.41–1.62 (m, 10H),
1.15–1.24 (m, 3H) ppm. 13C-NMR (CDCl3): δ = 151.1, 73.7, 68.6, 51.4, 34.5, 30.0, 27.0, 25.6, 25.3, 24.6
ppm. IR: ν 2920 (vs), 2849 (s), 1448 (m), 1355 (m), 1166 (m), 1131 (s), 993 (m), 907 (m), 874 (m) cm−1.
C13H24N2 (208.34): calcd. C 74.94, H 11.62, N 13.44; found C 75.10, H 11.73, N 13.61.
(R,R)-N-(2-Morpholinocyclohexyl)methanimine ((R,R)-4d): Yield 1.02 g (98%). Colorless crystals
(diisopropyl ether). M.p. 127–129 ◦C. [α]25D = −124.52 (c 0.40, CHCl3). 1H-NMR (CDCl3): δ = 7.30
(d, J = 17.1 Hz, 1H), 7.14 (d, J = 17.1 Hz, 1H), 3.59–3.66 (m, 2H), 3.51–3.55 (m, 2H), 2.93 (td, J = 9.8,
5.5 Hz, 1H), 2.50–2.60 (m, 3H), 2.40–2.46 (m, 2H), 1.83–1.88 (m, 1H), 1.75–1.79 (m, 1H), 1.65–1.70 (m,
1H), 1.57–1.63 (m, 2H), 1.16–1.26 (m, 3H) ppm. 13C-NMR (CDCl3): δ = 151.4, 72.5, 67.6, 67.0, 48.9,
34.6, 25.5, 24.6, 23.9 ppm. IR: ν 2920 (s), 2851 (s), 1450 (m), 1258 (m), 1112 (vs), 995 (s), 872 (m) cm–1.
C11H20N2O (196.29): calcd. C 67.31, H 10.27, N 14.27; found C 67.07, H 10.39, N 14.23.
4.3.2. Synthesis of Alkoxyformaldimines 4i–j—General Procedure
A solution of 3 mmol of the corresponding primary amine ((S)-MBOA or BOA) and 0.25 mL (ca.
3 mmol) of formaldehyde (as aqueous solution (37%)) in 40 mL benzene was heated in the Dean-Stark
apparatus until no formation of water was observed. After cooling to room temperature, the solvent
was evaporated and the colorless, oily liquids were used for further reactions without purification.
(S)-(α-Methylbenzyloxy)methanimine (4i): Yield 404 mg (90%). Colorless liquid. [α]25D = −11.90 (c 0.51,
CHCl3). 1H-NMR (CDCl3): δ = 7.38–7.33, 7.30–7.27 (2m, 4H, 1H, Ph), 7.08, 6.43 (2d, 2H, J = 8.5 Hz,
=CH2), 5.27 (q, J = 6.7 Hz, 1H), 1.56 (d, J = 6.7 Hz, 3H, Me) ppm. 13C-NMR (CDCl3): δ = 143.0 (t,
N=CH2), 137.4, 128.4, 127.6, 126.3 (s, 3d, Ph), 81.1 (d, CH), 21.8 (q, Me) ppm. HRMS (CI+): calcd for
C9H13NO [M + H]+ 150.0917; found 150.0919.
(Benzyloxy)methanimine (4j): Yield 360 mg (88%). Colorless liquid (ref. [41], bp 76 ◦C/15 mmHg).
1H-NMR (CDCl3): δ = 7.40–7.35, 7.34–7.30 (2m, 4H, 1H, Ph), 7.09, 6.47 (2d, 2H, J = 8.2 Hz, =CH2), 5.14
(s, 2H, -CH2-) ppm. 13C-NMR (CDCl3): δ = 137.4 (t, N=CH2), 137.3 (s, Ph), 128.3, 128.1, 127.8 (3d, Ph),
75.8 (t, -CH2-) ppm.
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4.4. Synthesis of Imidazole N-Oxides 6—General Procedure
A solution of 1.1 mmol of the respective formaldimine 4 and 1 mmol of α-hydroxyiminoketone
5 in 3 mL of glacial acetic acid was stirred magnetically overnight. The next day, 1 mL of aqueous
hydrochloric acid was added and the solution was stirred for 15 min. Then, the resulting solution was
evaporated to dryness, the solid residue was dissolved in 20 mL of dichloromethane, and the obtained
solution was neutralized with 20 mL of diluted aqueous sodium hydroxide. The organic layer was
separated, dried over mgSO4, filtrated, and evaporated. The resulting crude products were washed
with two portions (each ca. 10 mL) of diethyl ether, and after separation, the obtained thick oils or
amorphous solids were characterized spectroscopically and used for further transformations.
(R,R)-4,5-Dimethyl-1-[2-(pyrrolidin-1-yl)cyclohexyl]-1H-imidazole 3-oxide ((R,R)-6a): Yield 171.0 mg
(65%). Colorless, viscous oil. 1H-NMR (CDCl3): δ = 7.88 (s, 1H), 3.73 (td, J = 11.2, 3.5 Hz, 1H), 2.81–2.87
(m, 1H), 2.45–2.49 (m, 2H), 2.37–2.41 (m, 2H), 2.14 (s, 3H), 2.10 (s, 3H), 2.00–2.03 (m, 1H), 1.93–1.97 (m,
1H), 1.80–1.84 (m, 1H), 1.76–1.79 (m, 1H), 1.44–1.60 (m, 4H), 1.14–1.35 (m, 4H) ppm. 13C-NMR (CDCl3):
δ = 125.2, 123.0, 120.6, 62.1, 58.7, 48.0, 35.0, 25.2, 24.8, 24.6, 23.6, 8.8, 7.1 ppm. IR: ν 2927 (s), 1655 (m),
1448 (m), 1377 (m), 1332 (vs), 1191 (m), 1142 (m), 883 (s), 702 (s), 579 (s) cm−1. HRMS (ESI+): calcd for
C15H26N3O [M + H]+ 264.2076; found 264.2082.
(R,R)-4,5-Diphenyl-1-[2-(pyrrolidin-1-yl)cyclohexyl]-1H-imidazole 3-oxide ((R,R)-6b): Yield 360.0 mg
(93%). Yellowish crystals. M.p. 189–191 ◦C. 1H-NMR (CDCl3): δ = 8.12 (s, 1H), 7.49 (d, J = 7.9 Hz),
7.35–7.39 (m, 3H), 7.18–7.23 (m, 5H), 3.74 (td, J = 11.7, 4.2 Hz, 1H), 2.86 (td, J = 11.1, 3.5 Hz, 1H),
2.32–2.36 (m, 2H), 2.25–2.29 (m, 2H), 2.06–2.11 (m, 1H), 1.89–1.94 (m, 1H), 1.47–1.78 (m, 8H), 1.21–1.29
(m, 1H), 1.08–1.18 (m, 3H) ppm. 13C-NMR (CDCl3): δ = 130.7, 129.6, 129.3, 129.1, 128.9, 128.0, 127.9,
127.8, 127.3, 127.0, 124.2, 62.3, 58.7, 47.6, 35.4, 25.2, 24.6, 24.0, 23.56, 23.51 ppm. IR: ν 2931 (m), 2808 (s),
1448 (m), 1341 (m), 1321 (m), 1224 (m), 881 (m), 754 (s), 710 (s), 689 (vs), 658 cm−1. C25H29N3O·0.5 H2O
(387.52 + 9): calcd. C 75.72, H 7.62, N 10.60; found C 75.50, H 7.59, N 10.61.
(R,R)-4,5-Dimethyl-1-[2-(piperidin-1-yl)cyclohexyl]-1H-imidazole 3-oxide ((R,R)-6c): Yield 249.5 mg
(90%). Yellowish crystals. M.p. 68–71 ◦C. 1H-NMR (CDCl3): δ = 7.70 (s, 1H), 3.75 (td, J = 11.5, 3.8 Hz,
1H), 2.47–2.54 (m, 3H), 2.23–2.27 (m, 2H), 2.19 (s, 3H), 2.11 (s, 3H), 1.99–2.02 (m, 2H), 1.78–1.87 (m, 2H),
1.45–1.52 (m, 1H), 1.37–1.42 (m, 2H), 1.24–1.33 (m, 7H) ppm. 13C-NMR (CDCl3): δ = 124.9, 123.4, 120.8,
67.7, 56.6, 50.0, 34.9, 26.5, 25.4, 25.0, 24.7 (2C signals overlap), 8.9, 7.2 ppm. IR: ν 2926 (vs), 2853 (m),
1655 (br.m), 1450 (s), 1377 (m), 1331 (vs), 1103 (m), 881 (m), 702 (s), 579 (s) cm–1. HRMS (ESI+): calcd
for C16H28N3O [M + H]+ 278.2232; found 278.2234.
(S,S)-4,5-Dimethyl-1-[2-(piperidin-1-yl)cyclohexyl]-1H-imidazole 3-oxide ((S,S)-6c): Yield: 263.5 g
(95%). Yellowish crystals. M.p. 51–54 ◦C. 1H-NMR (CDCl3): δ = 7.87 (s, 1H), 3.70 (td, J = 11.5, 3.8 Hz,
1H), 2.51–2.56 (m, 1H), 2.41–2.46 (m, 2H), 2.27–2.21 (m, 2H), 2.12 (s, 3H), 2.06 (s, 3H), 1.92–1.96 (m, 2H),
1.71–1.80 (m, 2H), 1.46–1.53 (m, 1H), 1.29–1.35 (m, 2H), 1.18–1.25 (m, 7H) ppm. 13C-NMR (CDCl3):
δ = 124.7, 122.8, 120.6, 67.6, 56.3, 49.9, 34.8, 26.3, 25.2, 24.9, 24.51, 24.46, 8.7, 7.1 ppm. IR: ν 2928 (vs),
2855 (m), 1664 (br, m), 1450 (s), 1379 (s), 1332 (vs), 1101 (m), 881 (m), 704 (s), 581 (s) cm−1. HRMS (ESI+):
calcd for C16H28N3O [M + H]+ 278.2232; found 278.2238.
(R,R)-4,5-Diphenyl-1-[2-(piperidin-1-yl)cyclohexyl]-1H-imidazole 3-oxide ((R,R)-6d): Yield 261.0 mg
(65%). Yellowish crystals. M.p. 192–194 ◦C. 1H-NMR (CDCl3): δ = 8.00 (s, 1H), 7.57 (d, J = 7.5 Hz,
2H), 7.39–7.45 (m, 3H), 7.23–7.29 (m, 5H), 3.82 (td, J = 11.5, 3.8 Hz, 1H), 2.61 (td, J = 11.3, 3.3 Hz, 1H),
2.25–2.29 (m, 2H), 2.17–2.22 (m, 2H), 1.93–1.97 (m, 1H), 1.78–1.83 (m, 2H), 1.63–1.70 (m, 1H), 1.00–1.44
(m, 10H) ppm. 13C-NMR (CDCl3): δ = 130.6, 129.6, 129.2, 128.9, 128.2, 127.9, 127.7, 127.36, 127.28, 124.1,
68.2, 56.7, 49.7, 35.7, 26.5, 25.3, 25.0, 24.7, 24.0 ppm. IR: ν 2929 (s), 2855 (m), 1444 (m), 1342 (m), 1205
(w), 1101 (w), 1034 (w), 784 (s), 710 (s), 691 (s) cm−1. C26H31N3O (401.54): calcd. C 77.77, H 7.78, N
10.46; found C 77.56, H 7.88, N 10.59.
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(S,S)-4,5-Diphenyl-1-[2-(piperidin-1-yl)cyclohexyl]-1H-imidazole 3-oxide ((S,S)-6d): Yield: 333.0 mg
(83%) after purification on a short column. Yellowish crystals. M.p. 198–199 ◦C. 1H-NMR (CDCl3):
δ = 8.03 (s, 1H), 7.56 (d, J = 7.5 Hz, 2H), 7.40–7.45 (m, 3H), 7.23–7.29 (m, 5H), 3.81 (td, J = 11.6, 3.8 Hz,
1H), 2.61 (td, J = 11.3, 3.4 Hz, 1H), 2.24–2.28 (m, 2H), 2.17–2.22 (m, 2H), 1.92–1.97 (m, 1H), 1.78–1.83 (m,
2H), 1.68 (qd, J = 12.5, 3.3 Hz, 1H), 1.06–1.44 (m, 10H) ppm. 13C-NMR (CDCl3): δ = 130.5, 129.6, 129.3,
128.95, 128.89, 127.95, 127.91, 127.79, 127.4, 127.1, 68.0, 56.9, 49.6, 35.4, 26.5, 25.3, 24.9, 24.6, 24.0 ppm.
IR: ν 2928 (s), 2853 (m), 1444 (m), 1342 (m), 1205 (m), 1103 (m), 1034 (w), 786 (s), 712 (s), 693 (vs) cm−1.
HRMS (ESI+): calcd for C26H32N3O [M + H]+ 402.2545; found 402.2546.
(R,R)-1-[2-(Azepan-1-yl)cyclohexyl]-4,5-dimethyl-1H-imidazole 3-oxide ((R,R)-6e): Yield 227.1 g (78 %).
Colorless, viscous oil. 1H-NMR (CDCl3): δ = 7.74 (s, 1H), 3.66 (td, J = 11.2, 3.9 Hz, 1H), 2.63–2.67 (m,
1H), 2.53–2.58 (m, 2H), 2.37–2.42 (m, 2H), 2.11 (s, 3H), 2.06 (s, 3H), 1.91–1.96 (m, 2H), 1.71–1.79 (m, 2H),
1.15–1.53 (m, 12H) ppm. 13C-NMR (CDCl3): δ = 124.7, 123.4, 120.1, 67.2, 57.3, 50.4, 35.0, 29.5, 26.5, 25.2,
25.0, 24.7, 8.6, 6.9 ppm. IR: ν 2924 (vs), 2853 (m), 1654 (s), 1448 (s), 1332 (s), 725 (vs), 704 (vs), 581 (m)
cm–1. HRMS (ESI+): calcd for C17H30N3O [M + H]+ 292.2389; found 292.2398.
(R,R)-1-[2-(Azepan-1-yl)cyclohexyl]-4,5-diphenyl-1H-imidazole 3-oxide ((R,R)-6f): Yield: 369.6 mg
(89%). Yellowish crystals. M.p. 64–68 ◦C. 1H-NMR (CDCl3): δ = 8.06 (s, 1H), 7.50 (d, J = 7.7 Hz,
2H), 7.37–7.41 (m, 3H), 7.19–7.24 (m, 5H), 3.75 (td, J = 11.4, 3.7 Hz, 1H), 2.71 (td, J = 11.3, 3.5 Hz, 1H),
2.35–2.44 (m, 4H), 2.13–2.17 (m, 1H), 1.88–1.93 (m, 1H), 1.72–1.78 (m, 3H), 1.09–1.64 (m, 11H) ppm.
13C-NMR (CDCl3): δ = 130.5, 129.7, 129.4, 129.0, 128.00, 127.96, 127.5, 127.0, 126.7, 125.9, 125.5, 68.3,
57.9, 50.5, 35.7, 29.7, 26.7, 25.2, 24.9 ppm (one signal of sp3 C atom not observed due to overlap). IR: ν
2926 (s), 2855 (w), 1672 (m), 1444 (m), 1224 (w), 712 (s), 693 (br, s) 635 (m), 508 (br, m), 451 (br, m) cm−1.
HRMS (ESI+): calcd for C17H34N3O [M + H]+ 416.2702; found 416.2708.
(R,R)-1-(2-Morpholinocyclohexyl)-4,5-dimethyl-1H-imidazole 3-oxide ((R,R)-6g): Yield: 240.1 mg (86%).
Yellowish crystals. M.p. 85–87 ◦C. 1H-NMR (CDCl3): δ = 9.06 (s, 1H), 3.76–3.82 (m, 1H), 3.58–3.66 (m,
1H), 3.43–3.48 (m, 2H), 3.36–3.40 (m, 2H), 3.10 (td, J = 11.1, 3.1 Hz, 1H), 2.49–2.54 (m, 2H), 2.39–2.43 (m,
2H), 2.15 (s, 3H), 2.09 (s, 3H), 1.95–2.04 (m, 2H), 1.86–1.93 (m, 1H), 1.76–1.82 (m, 2H), 1.42–1.50 (m, 1H),
1.20–1.28 (m, 2H) ppm. 13C-NMR (CDCl3): δ = 126.2, 124.4, 121.0, 67.3, 66.0, 57.2, 48.8, 34.2, 25.3, 24.9,
24.5, 8.9, 7.1 ppm. IR ν 2929 (s), 2855 (m), 1654 (w), 1627 (br, w), 1450 (m), 1332 (s), 1112 (vs), 926 (m),
861 (m), 725 (vs) cm−1. HRMS (ESI+): calcd for C15H26N3O2 [M + H]+ 280.2025; found 280.2026.
(R,R)-1-(2-Morpholinocyclohexyl)-4,5-diphenyl-1H-imidazole 3-oxide ((R,R)-6h): Yield: 266.3 mg
(66%). Yellowish crystals. M.p. 152–155 ◦C. 1H-NMR (CDCl3): δ = 8.08 (s, 1H), 7.54 (d, J = 7.2 Hz, 2H),
7.38–7.43 (m, 3H), 7.24–7.29 (m, 3H), 7.19 (d, J = 6.9 Hz, 2H), 3.84 (td, J = 11.6, 4.0 Hz, 1H), 3.44–3.51 (m,
4H), 2.62 (td, J = 11.3, 3.1 Hz, 1H), 2.22–2.28 (m, 5H), 1.94–1.98 (m, 1H), 1.81–1.86 (m, 2H), 1.69–1.76 (m,
1H), 1.25–1.33 (m, 1H), 1.16–1.24 (m, 1H), 1.08–1.15 (m, 1H) ppm. 13C-NMR (CDCl3): δ = 130.4, 129.7,
129.3, 129.0, 127.99, 127.92, 127.88, 127.4, 127.1, 123.9, 68.1, 67.3, 56.3, 48.6, 35.2, 25.2, 24.8, 24.2 ppm
(one signal of an sp2 C atom not observed due to overlap). IR: ν 2926 (s), 2857 (m), 1448 (m), 1341 (m),
1109 (s), 861 (s), 766 (s), 695 (vs), 665 (s), 633 (s) cm−1. C25H29N3O2·0.5 H2O (412.52): calcd. C 72.79, H
7.33, N 10.18; found C 72.68, H 7.25, N 9.90.
4.5. Synthesis of 3-Benzyloxyimidazolium Bromides 7—General Procedure
A solution of 0.5 mmol of crude imidazole N-oxide 6 and 86 mg (0.5 mmol) benzyl bromide in
1 mL of CHCl3 was stirred magnetically overnight at room temperature. The next day, the solvent
was evaporated and the obtained crude imidazolium salts were triturated with diethyl ether. The
ethereal phase was separated and the non-soluble imidazolium salts 7 were used for the generation
of carbenes 8 and their reaction with elemental sulfur without further purification. Whereas di-Me
substituted imidazolium salts formed viscous, thick oils, the corresponding di-Ph derivatives were
obtained as amorphous solids. The structures of selected imidazolium salts were confirmed by running
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the 1H-NMR spectra. A representative example of the 1H-NMR spectra registered for 7e is described
below and the scanned spectrum is presented in the Supplementary Materials.
(R,R)-1-[2-(Azepan-1-yl)cyclohexyl]-4,5-dimethyl-3-benzyloxy-1H-imidazolium bromide((R,R)-7e):
1H-NMR (CDCl3): δ = 11.09 (s, 1H), 7.51 (d, J = 6.9 Hz, 2H), 7.27–7.37 (m, 3H), 5.70 (d, J= 10.0 Hz,
1H), 5.57 (d, J= 10.0 Hz, 1H), 3.91 (br., 1H), 3.62 (br., 1H), 2.60 (br., 4H), 2.13–2.17 (m, 1H), 2.13 (s, 3H),
2.02–2.06 (m, 1H), 1.96–2.01 (m, 1H), 1.91 (s, 3H), 1.80–1.85 (m, 1H), 1.74–1.79 (m, 1H), 1.55–1.63 (m,
1H), 1.47 (br., 2H), 1.29 (br., 6H), 1.18 (br., 2H) ppm.
4.6. Synthesis of Non-Symmetric Imidazole-2-Thiones 9—General Procedure
The crude imidazolium salt 7 obtained from 0.5 mmol of the corresponding imidazole N-oxide
6 and 86 mg (0.5 mmol) of benzyl bromide according to the general procedure (see above) was
dissolved in 1 mL of dry pyridine. Next, 38 mg (1.2 mmol) of elemental sulfur and 122 mg (1.2 mmol)
of triethylamine were added to the magnetically stirred, homogenous solution. Stirring at room
temperature was continued overnight. Next day, pyridine was removed under reduced pressure and
the residual semi-solid material was purified by preparative thin layer chromatography with silica
gel. A mixture of dichloromethane and methanol (99:1) was used as an eluent. Imidazole-2-thiones 9
formed a single fraction with Rf ca. 0.3. Solid products were additionally purified by crystallization.
(R,R)-3-Benzyloxy-4,5-dimethyl-1-[2-(pyrrolidin-1-yl)cyclohexyl]-1,3-dihydro-2H-imidazole -2-thione
((R,R)-9a): Yield: 238.8 mg (62%). Colorless, viscous oil, purified by chromatography. [α]25D = −91.15 (c
0.40, CHCl3). 1H-NMR (CDCl3): δ = 7.32–7.44 (m, 5H), 5.75–5.80 (m, 1H), 5.42 (d, J = 10.0 Hz, 1H), 5.28
(d, J = 10.0 Hz, 1H), 4.57–4.63 (m, 1H), 3.06–3.11 (m, 1H), 2.83–3.02 (m, 3H), 2.36 (s, 3H), 2.26–2.31 (m,
1H), 1.72–2.13 (m, 8H), 1.81 (s, 3H), 1.38–1.51 (m, 3H) ppm. 13C-NMR (CDCl3): δ = 155.1, 133.3, 130.2,
129.5, 128.5, 121.1, 118.4, 78.1, 60.7, 58.4, 52.2, 29.6, 29.4, 24.1, 23.7, 22.6, 9.9, 7.7 ppm. IR ν 2929 (s), 2862
(m), 1377 (br, s), 1401 (br, s), 1321 (vs), 1140 (br, m), 1025 (m),954 (m), 913 (m), 836 (w), 751 (s), 697 (vs),
606 (w), 483 (s) cm−1. HRMS (ESI+): calcd for C22H32N3OS [M + H]+ 386.2266; found 386.2274.
(R,R)-3-Benzyloxy-4,5-diphenyl-1-[2-(pyrrolidin-1-yl)cyclohexyl]-1,3-dihydro-2H-imidazole -2-thione
((R,R)-9b): Yield: 356.8 g (70%). Colorless crystals. M.p. 285–286 ◦C (from MeOH/CH2Cl2) (decomp.).
[α]25D = −36.65 (c 0.40, CHCl3). 1H-NMR (CDCl3): δ = (signals for both rotamers) 6.96–7.45 (m, 15H),
4.95–5.47 (m, 3H), 3.44 and 3.74 (br., 1H), 2.14–2.70 (m, 4H), 0.80–1.96 (m, 12H) ppm. 13C-NMR (CDCl3):
δ = (signals for both rotamers) 157.3, 156.1, 133.2, 132.6, 131.1, 130.6, 129.4, 129.3, 129.0, 128.7, 128.2,
128.0, 127.8, 126.4, 125.2, 124.5, 77.4, 61.7, 58.2, 55.0, 46.4, 33.3, 29.4, 26.0, 25.8, 25.0, 24.8, 23.8, 23.6, 22.1
ppm. IR: ν 2929 (m), 2797 (m), 1425 (m), 1358 (m), 1332 (m), 1306 (br, m), 1187 (w), 1073 (w), 965 (m),
911 (m), 786 (m), 753 (s), 695 (vs), 598 (m), 506 (m) cm−1. HRMS (ESI+): calcd. for C32H36N3OS [M +
H]+ 510.2579; found 510.2595. C32H35N3OS (509.70): calcd. C 75.40, H 6.92, N 8.24, S 6.30; found C
75.30, H 6.91, N 8.24, S 6.14.
(R,R)-3-Benzyloxy-4,5-dimethyl-1-[2-(piperidin-1-yl)cyclohexyl]-1,3-dihydro-2H-imidazole-2 -thione
((R,R)-9c): Yield: 239.5 mg (60%). Colorless, viscous oil, purified by chromatography. [α]25D = −16.53 (c
0.40, CHCl3). 1H-NMR (CDCl3): δ = 7.47 (d, J = 7.7 Hz, 2H), 7.32–7.37 (m, 3H), 5.46 (d, J = 10.5 Hz, 1H),
5.32 (d, J = 10.5 Hz, 1H), 5.27 (td, J = 11.6, 3.7 Hz, 1H), 2.89 (td, J = 11.4, 2.8 Hz, 1H), 2.74–2.79 (m, 2H),
2.23–2.27 (m, 2H), 2.08 (s, 3H), 1.94–2.02 (m, 2H), 1.83–1.88 (m, 1H), 1.73–1.78 (m, 1H), 1.70 (s, 3H),
1.59 (qd, J = 12.5, 3.7 Hz, 1H), 1.29–1.52 (m, 8H), 1.17–1.25 (m, 1H) ppm. 13C-NMR (CDCl3): δ = 156.5,
134.2, 130.5, 129.1, 128.4, 119.4, 117.9, 77.6, 65.9, 58.5, 49.4, 32.0, 26.8, 25.9, 25.7, 24.9, 24.6, 10.5, 7.2 ppm.
IR: ν 2927 (vs), 2853 (m), 1403 (s), 1377 (s), 1330 (s), 1211 (m), 1105 (m), 963 (m), 911 (m), 749 (vs), 699
(vs), 479 (br.s) cm−1. HRMS (ESI+) calcd. for C23H34N3OS [M + H]+ 400.2423; found: 400.2424.
(S,S)-3-Benzyloxy-4,5-dimethyl-1-[2-(piperidin-1-yl)cyclohexyl]-1,3-dihydro-2H-imidazole-2 -thione
((S,S)-9c): Yield: 187.6 mg (47%). Colorless, viscous oil, purified by chromatography. [α]25D = +26.13
(c 0.40, CHCl3). 1H-NMR (CDCl3): δ = 7.46 (d, J = 7.5 Hz, 2H), 7.32–7.37 (m, 3H), 5.46 (d, J = 10.5 Hz,
1H), 5.31 (d, J = 10.5 Hz, 1H), 5.26 (td, J = 11.9, 4.2 Hz, 1H), 2.89 (td, J = 11.4, 2.8 Hz, 1H), 2.74–2.78 (m,
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2H), 2.23–2.27 (m, 2H), 2.07 (s, 3H), 1.94–2.03 (m, 2H), 1.83–1.87 (m, 1H), 1.73–1.77 (m, 1H), 1.68 (s, 3H),
1.58 (qd, J = 12.5, 3.7 Hz, 1H), 1.27–1.51 (m, 8H), 1.17–1.25 (m, 1H) ppm. 13C-NMR (CDCl3): δ = 156.3,
134.2, 130.5, 129.1, 128.4, 119.4, 117.9, 77.6, 65.9, 58.5, 49.4, 32.0, 26.8, 25.8, 25.7, 24.9, 24.5, 10.5, 7.2 ppm.
IR: ν 2927 (vs), 2853 (m), 1403 (s), 1377 (s), 1328 (s), 1211 (m), 1105 (m), 963 (m), 911 (w), 749 (vs), 697
(vs), 479 (br, s) cm−1. HRMS (ESI+): calcd for C23H34N3OS [M + H]+ 400.2423; found 400.2426.
(R,R)-3-Benzyloxy-4,5-diphenyl-1-[2-(piperidin-1-yl)cyclohexyl]-1,3-dihydro-2H-imidazole-2 -thione
((R,R)-9d): Yield 429.4 mg (82%). Colorless crystals. M.p. 283–285 ◦C (MeOH/CH2Cl2) (decomp.).
[α]25D = −26.77 (c 0.40, CHCl3). 1H-NMR (CDCl3): δ = (signals for both rotamers in ca. 1:2 ratio)
7.07–7.41 (m, 15H), 5.40 and 5.32 (d, J = 9.4 Hz, 1H), 4.61–4.67 (m) and 5.36 (td, J = 11.8, 3.4 Hz, total:
1H), 4.98 and 5.12 (br. d, J = 9.4 Hz, 1H), 0.77–3.76 (m, 18H) ppm. 13C-NMR (CDCl3): δ = (signals for
both rotamers) 157.6, 156.7, 133.2, 133.1, 132.4, 130.6, 130.42, 130.38, 129.5, 129.3, 129.22, 129.15, 128.92,
128.87, 128.84, 128.6, 128.4, 128.3, 128.1, 128.02, 127.97, 127.8, 127.7, 126.9, 126.6, 126.40, 126.31, 124.9,
124.6, 124.3, 77.51, 77.49, 64.4, 59.9, 59.7, 49.1 (br.), 48.8 (br.), 33.2, 29.6, 27.1, 26.8, 26.0, 25.7, 25.2, 24.94,
24.91, 24.6, 23.5 ppm. IR: ν 2924 (s), 2849 (w), 1442 (w), 1397 (s), 1321 (s), 1207 (m), 959 (m), 760 (s), 691
(vs), 596 (m), 568 (m), 475 (w) cm−1. C33H37N3OS (523.73): calcd. C 75.68, H 7.13, N 8.02, S 6.12; found
C 75.63, H 7.17, N 8.00. S 6.00.
(S,S)-3-Benzyloxy-4,5-diphenyl-1-[2-(piperidin-1-yl)cyclohexyl]-1,3-dihydro-2H-imidazole-2 -thione
((S,S)-9d): Yield 324.7 mg (62%). Viscous oil (after chromatography). [α]25D = +22.42 (c 0.40, CHCl3).
1H-NMR (CDCl3): δ = (signals for both rotamers in ca. 1:2 ratio) 7.07–7.41 (m, 15H), 5.41 and 5.32 (d,
J = 9.3 Hz, 1H), 4.61–4.67 and 5.33–5.38 (m, 1H), 4.98 and 5.12 (br. d, J = 9.3 Hz, 1H), 0.78–3.74 (m, 18H)
ppm. 13C-NMR (CDCl3): δ = (signals for both rotamers) 157.6, 156.7, 133.14, 133.06, 132.4, 130.6, 130.43,
130.40, 129.5, 129.4, 129.2, 128.93, 128.89, 128.88, 128.7, 128.5, 128.13, 128.05, 127.8, 127.7, 126.9, 126.7,
126.4, 125.9, 124.9, 124.6, 124.4, 77.53, 77.51, 64.4, 60.0, 59.7, 49.2 (br.), 33.2, 29.6, 27.1, 26.8, 26.0, 25.7,
25.2, 24.9, 24.6, 23.5 ppm. IR: ν 2927 (s), 2853 (m), 1444 (w), 1396 (w), 1321 (m), 1207 (m), 959 (m), 753
(s), 693 (vs), 596 (m), 568 (m), 475 (w) cm−1. HRMS (ESI+): calcd for C33H38N3OS [M + H]+ 524.2736;
found 524.2743. C33H37N3OS (523.73): calcd. C 75.68, H 7.13, N 8.02, S 6.12; found C 75.64, H 7.10, N
8.06, S 5.92.
(R,R)-3-Benzyloxy-1-[2-(azepan-1-yl)cyclohexyl]-4,5-dimethyl-1,3-dihydro-2H-imidazole-2-thione
((R,R)-9e): Yield: 173.7 mg (42 %).Viscous oil. [α]25D = −28.85 (c 0.40, CHCl3). 1H-NMR (CDCl3):
δ = 7.46–7.48 (m, 2H), 7.33–7.36 (m, 3H), 5.38 (d, J = 10.4 Hz, 1H), 5.32 (d, J = 10.4 Hz, 1H), 5.21 (td,
J = 11.6, 3.4 Hz, 1H), 2.97 (td, J = 11.6, 2.7 Hz, 1H), 2.79–2.84 (m, 2H), 2.40–2.44 (m, 2H), 2.11 (s, 3H),
1.93–2.01 (m, 2H), 1.82–1.86 (m, 1H), 1.73–1.77 (m, 1H), 1.74 (s, 3H), 1.57 (qd, J = 12.4, 3.3 Hz, 1H),
1.31–1.52 (m, 10H) 1.16–1.25 (m, 1H) ppm. 13C-NMR (CDCl3): δ = 156.6, 134.2, 130.3, 129.1, 128.4,
119.2, 118.1, 77.9, 67.1, 59.4, 51.2, 32.1, 30.0, 26.6, 25.8, 25.7, 25.5, 10.6, 7.2 ppm. IR: ν 2922 (vs), 2853 (m),
1403 (s), 1377 (s), 1328 (s), 1170 (w), 1133 (w), 959 (m), 907 (m), 749 (vs), 697 (vs) cm−1. C24H35N3OS
(413.62): calcd. C 69.69, H 8.53, N 10.16., S 7.75; found C 69.47, H 8.62, N 10.21, S 7.59.
(R,R)-3-Benzyloxy-1-[2-(azepan-1-yl)cyclohexyl]-4,5-diphenyl-1,3-dihydro-2H-imidazole-2-thione
((R,R)-9f): Yield: 376.4 mg (70%). Colorless crystals. M.p. 264–267 ◦C (MeOH/CH2Cl2) (decomp.).
[α]25D = −27.17 (c 0.40, CHCl3). 1H-NMR (CDCl3): δ = (signals for both rotamers in ca. 1:2 ratio)
7.05–7.38 (m, 15H), 5.32 and 4.72 (td, J = 11.5, 3.6 Hz, 1H), 5.31 and 5.21 (d, J = 9.3 Hz, 1H), 5.02 (br.)
and 5.15 (d, J = 9.3 Hz, 1H), 3.69 (td, J = 11.7, 3.0 Hz, 0.3H), 3.28–3.36 (m, 0.3H), 2.75–2.80 (m, 1H),
2.43–2.47 (m, 0.7H), 2.29–2.32 (m, 0.7H), 1.34–2.21 (m, 15H), 1.16 and 0.98 (qd, J = 12.8, 3.5 Hz, 1H),
1.03–1.11 and 0.73–0.82 (m, 1H) ppm. 13C-NMR (CDCl3): δ = 158.0, 157.0, 133.2, 133.1, 132.5, 130.6,
130.37, 130.3, 129.6, 129.4, 129.2, 129.1, 128.9, 128.6, 128.15, 128.13, 128.10, 128.07, 127.9, 127.8, 127.7,
126.6, 126.4, 126.0, 125.0, 124.7, 77.62, 77.58, 66.1, 61.4, 60.5, 51.4 (br.), 50.5, 33.3, 30.05, 29.97, 29.8, 26.9,
26.6, 26.4, 26.0, 25.8, 25.23, 25.17 ppm. IR: ν 2924 (s), 2853 (m), 1446 (m), 1356 (m), 1332 (m), 1073 (w),
963 (w), 752 (s), 693 (vs) cm−1. C34H39N3OS (537.76): calcd. C 75.94, H 7.31, N 7.81, S 5.96; found C
75.91, H 7.45, N 8.01, S 5.86.
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(R,R)-3-Benzyloxy-1-(2-morpholinocyclohexyl)-4,5-dimethyl-1,3-dihydro-2H-imidazole-2-thione
((R,R)-9g): Yield 135 mg (67%). Colorless crystals. M.p. 122–124 ◦C (after chromatographic separation).
[α]25D = −21.22 (c 0.40, CHCl3). 1H-NMR (CDCl3): δ = 7.43–7.46 (m, 2H), 7.33–7.37 (m, 3H), 5.44
(d, J = 10.4 Hz, 1H), 5.30 (d, J = 10.4 Hz, 1H), 5.27 (td, J = 11.9, 3.7 Hz, 1H), 3.52–3.57 (m, 2H), 3.45–3.50
(m, 2H), 2.92 (dt, J = 11.4, 3.2 Hz, 1H), 2.85–2.90 (m, 2H), 2.30–2.34 (m, 2H), 2.08 (s, 3H), 1.97–2.02 (m,
2H), 1.85–1.90 (m, 1H), 1.75–1.80 (m, 1H), 1.72 (s, 3H), 1.62 (qd, J = 12.4, 3.8 Hz, 1H), 1.42–1.51 (m, 1H),
1.32–1.40 (m, 1H), 1.17–1.27 (m, 1H) ppm. 13C-NMR (CDCl3): δ = 156.5, 134.1, 130.5, 129.3, 128.6, 119.9,
117.7, 77.8, 67.7, 65.4, 58.1, 48.6, 31.9, 25.8, 25.5, 24.5, 10.7, 7.3 ppm. IR: ν 2935 (br, m), 2851 (m) 2816
(w), 1451 (m), 1407 (s), 1334 (s), 1269 (s), 1146 (m), 1108 (vs), 915 (m), 855 (m), 754 (vs), 702 (m) cm−1.
C22H31N3O2S (401.56): calcd. C 65.80, H 7.78, N 10.46, S 7.98; found C 65.71, H 7.90, N 10.59, S 7.84.
(R,R)-3-Benzyloxy-1-(2-morpholinocyclohexyl)-4,5-diphenyl-1,3-dihydro-2H-imidazole-2-thione
((R,R)-9h): Yield 213 mg (81%). Colorless crystals. M.p. 279–281 ◦C (MeOH/CH2Cl2) (decomp.).
[α]25D = −43.58 (c 0.40, CHCl3). 1H-NMR (CDCl3): δ = (signals for both rotamers in ca. 1:1.2 ratio)
7.07–7.43 (m, 15H), 5.40 and 5.33 (d, J = 9.4 Hz, 1H), 5.37 and 4.72 (td, J = 11.8, 3.3 Hz, 1H), 5.09 and
4.92 (d, J = 9.4 Hz, 1H), 3.75 and 3.43 (td, J = 11.7, 3.7 Hz, 1H), 3.44–3.69 (m, 4H), 2.78 and 2.43 (br., 2H),
2.09–2.28 (m, 3H), 1.87–1.93 and 2.01–2.06 (m, 1H), 1.66–1.78 (m, 3H), 1.40–1.49 (m, 1H), 1.20–1.27
and 0.92–1.00 (m, 1H), 1.09–1.17 and 0.81–0.89 (m, 1H) ppm. 13C-NMR (CDCl3): δ = (signals for both
rotamers) 157.9, 156.9, 133.13, 133.07, 132.5, 130.6, 130.5, 130.4, 129.6, 129.5, 129.4, 129.3, 129.1, 129.04,
129.02, 128.8, 128.3, 128.0, 127.9, 126.5, 126.34, 126.29, 125.3, 124.5, 77.72, 77.66, 68.0, 67.8, 63.8, 59.8,
59.47, 59.43, 48.3, 33.2, 29.6, 25.93, 25.75, 25.2, 25.0, 24.9, 23.7 ppm. IR: ν 2924 (br m), 2853 (m), 1401 (m),
1360 (w), 1323 (m), 1112 (s), 965 (m), 861 (m), 762 (s), 699 (vs) cm−1. C32H35N3O2S (525.70): calcd. C
73.11, H 6.72, N 7.99; S 6.10; found C 73.12, H 6.76, N 7.93, S 6.03.
4.7. Synthesis of Imidazole N-Oxides 10a–d
A solution of diacetyl monooxime (5a, 354 mg, 3.5 mmol) and the corresponding formaldimine
4 (3.0 mmol) in EtOH (10 mL) was refluxed for 3 h. The solvents were removed in vacuo, and
the resulting oil was washed with Et2O (3 × 20 mL). The crude product 10 was either purified by
column chromatography on silica gel using AcOEt/MeOH mixtures as the eluent or by recrystallization
from the appropriate solvents to give spectroscopically pure imidazole N-oxides isolated as colorless
materials. Compounds 10a [21] and 10c [22] were prepared following the analogous method, while
imidazole N-oxide 10d was obtained in two steps by condensation of 5a with methyl glycinate-derived
formaldimine of type 4 followed by aminolysis of the resulting product with α-MBA as described [22];
the NMR spectra of the obtained samples matches the data reported in the literature.
(R)-1-(2-Hydroxy-1-phenylethyl)-4,5-dimethylimidazole 3-oxide (10b): Yield 474 mg (68%). Off-white
solid. M.p. 198–200 ◦C (CH2Cl2/Et2O) (decomp.). [α]20D = +49.1 (c 0.22, CHCl3). 1H-NMR (CDCl3):
δ = 9.17 (s, 1H, C(2)H), 8.72 (br.s, 1H, OH), 7.01–7.04, 7.27–7.35 (2m, 2H, 3H, Ph), 5.14 (dd, J = 3.8, 10.7
Hz, 1H, CHPh), 4.21 (dd, J = 10.7, 13.4 Hz, 1H, CH2O), 3.95 (dd, J = 3.8, 13.4 Hz, 1H, CH2O), 1.84, 2.10
(2s, 3H each, 2Me) ppm. 13C-NMR (CDCl3): δ = 136.6 (s, Ph), 128.3, 129.0 (2d, 3CH, Ph), 126.9 (d, 2CH,
Ph), 126.4 (s, C(4)), 124.9 (d, C(2)), 122.0 (s, C(5)), 63.9 (d, CHPh), 63.6 (t, CH2O), 7.0, 8.9 (2q, 2Me) ppm.
IR (neat): ν 3110 (s), 3025–2926 (br, m), 1450 (m), 1405 (m), 1351 (s), 1325 (m), 1208 (m), 1064 (s) cm−1.
ESI-MS (m/z): 465.4 (100, [2M + H]+), 233.3 (47, [M + H]+). C13H16N2O2 (232.28): calcd. C, 67.22; H,
6.94; N, 12.06; found: C 67.05, H 6.95, N 12.22.
4.8. Synthesis of Imidazolium Bromides 11a–d
To a solution of imidazole N-oxide 10 (1.0 mmol) in dry CH2Cl2 (1.0 mL) was added an excess of
1-bromobutane (548 mg, 4.0 mmol) and the resulting mixture was stirred until the starting material
was fully consumed (TLC monitoring: SiO2, EtOAc/MeOH 7:1). The solvents were removed under
reduced pressure to give the corresponding imidazolium bromide 11 quantitatively, which was used
for the next step without further purification.
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(S)-3-Butoxy-1-(2-hydroxypropyl)-4,5-dimethylimidazolium bromide [23] (11a): Reaction time: 2
d. Pale yellow oil. [α]20D = +16.0 (c 0.74, CHCl3).
1H-NMR (CDCl3): δ = 10.00 (s, 1H, C(2)H), 4.91 (br.d,
J ≈ 5.9 Hz, 1H, OH), 4.47 (td, J = 2.1, 6.5 Hz, 2H, OCH2, Bu), 4.34 (dd, J = 9.1, 14.0 Hz, 1H, NCH2), 4.22
(dd, J = 2.6, 14.0 Hz, 1H, NCH2), 4.16–4.22 (m, 1H, CHCH3), 2.26, 2.27 (2s, 3H each, 2Me), 1.77–1.81
(m, 2H, Bu), 1.47–1.43 (m, 2H, Bu), 1.34 (d, J = 6.3 Hz, 3H, CHCH3), 0.98 (t, J = 7.4 Hz, 3H, CH3, Bu)
ppm. 13C-NMR (CDCl3): δ = 131.4 (br.d, C(2)), 123.6, 124.7 (2s, C(4), C(5)), 82.7 (t, OCH2, Bu), 64.8 (d,
CHCH3), 53.5 (t, NCH2), 29.6 (t, CH2, Bu), 20.4 (q, CHCH3), 18.7 (t, CH2, Bu), 13.6 (q, CH3, Bu), 7.1, 8.9
(2q, 2Me) ppm. IR (neat): ν3308 (s), 2990–2876 (br, s), 1670 (m), 1634 (m), 1545 (m), 1457 (m), 1377 (m),
1139 (s), 1072 (s), 936 (s) cm−1.
(R)-3-Butoxy-1-(2-hydroxy-1-phenylethyl)-4,5-dimethylimidazolium bromide (11b): Reaction time: 2
d. Yellow solid. M.p. 124–127 ◦C. [α]25D = +83.5 (c 1.79, CHCl3). 1H-NMR (CDCl3): δ = 10.50 (s, 1H,
C(2)H), 7.15–7.18, 7.32–7.38 (2m, 2H, 3H, Ph), 5.61 (dd, J = 3.8, 10.1 Hz, 1H, CHPh), 5.46 (br.s, 1H, OH),
4.80 (pseudo-q, J ≈ 6.6 Hz, 1H, OCH2, Bu), 4.52–4.59 (m, 2H, CH2OH (1H), OCH2 (1H)), 4.10 (dd, J = 3.8,
13.2 Hz, 1H, CH2OH), 2.06, 2.24 (2s, 3H each, 2Me), 1.79–1.84 (m, 2H, Bu), 1.49–1.55 (m, 2H, Bu), 0.98 (t,
J = 7.4 Hz, 3H, CH3, Bu) ppm. 13C-NMR (CDCl3): δ = 134.2 (s, Ph), 131.4 (dbr, C(2)), 126.7, 129.3, 129.5
(3d, 5CH, Ph), 124.3, 125.0 (2s, C(4), C(5)), 83.2 (t, OCH2, Bu), 64.9 (d, CHPh), 62.4 (t, CH2OH), 29.8 (t,
CH2, Bu), 18.8 (t, CH2, Bu), 13.7 (q, CH3, Bu), 7.1, 9.1 (2q, 2Me) ppm. IR (neat): ν 3248 (vs), 3027–2876
(br, s), 1636 (m), 1541 (m), 1448 (s), 1359 (m), 1066 (s), 935 (s) cm−1.
(R)-3-Butoxy-4,5-dimethyl-1-[1-(methoxycarbonyl)ethyl]imidazolium bromide [23] (11c): Reaction
time: 2 d. Pale yellow oil. [α]20D = −16.6 (c 0.51, CHCl3). The NMR data in accordance with those
reported in [23].
(R)-3-Butoxy-4,5-dimethyl-1-[(N-phenylethyl)acetamido]imidazolium bromide (11d): Reaction time: 4
d. Pale yellow oil. [α]20D = +51.2 (c 0.52, CHCl3).
1H-NMR (CDCl3): δ = 9.84 (s, 1H, C(2)H), 9.29 (d,
J = 7.8 Hz, 1H, NH), 7.14–7.17, 7.23–7.26, 7.39–7.42 (3m, 1H, 2H, 2H, Ph), 5.35, 5.45 (AB system, J = 16.1
Hz, 2H, NCH2), 4.95 (dq, J = 7.1, 7.8 Hz, 1H, CH(Ph)CH3), 4.32 (td, J = 1.4, 6.5 Hz, 2H, OCH2, Bu), 2.14,
2.17 (2s, 3H each, 2Me), 1.71–1.76 (m, 2H, Bu), 1.53 (d, J = 7.1 Hz, 3H, CH(Ph)CH3), 1.42–1.48 (m, 2H,
Bu), 0.94 (t, J = 7.4 Hz, 3H, CH3, Bu) ppm. 13C-NMR (CDCl3): δ = 163.6 (s, C=O), 143.6 (s, Ph), 131.4
(br.d, C(2)), 126.3, 126.9, 128.4 (3d, 5CH, Ph), 123.3, 125.9 (2s, C(4), C(5)), 82.6 (t, OCH2, Bu), 50.3 (d,
CH(Ph)CH3), 49.7 (t, NCH2), 29.5 (t, CH2, Bu), 22.4 (q, CH(Ph)CH3), 18.6 (t, CH2, Bu), 13.6 (q, CH3, Bu),
7.0, 8.7 (2q, 2Me) ppm. IR (neat): ν 3200 (m), 3032–2872 (br, s), 1679 (vs, C=O), 1547 (s), 1448 (m), 1377
(m), 1250 (m) cm−1.
4.9. Synthesis of Imidazole-2-thiones 13a–d and 15a–d
To a solution of the respective imidazolium bromide (1.0 mmol) in dry pyridine (4.0 mL) was
added triethylamine (150 µL) followed by elemental sulfur (33 mg, 1.1 mmol), and the resulting mixture
was stirred overnight. The solvents were removed under reduced pressure, and the crude product was
purified by standard column chromatography to give imidazole-2-thione of type 13 or 15, respectively.
(S)-3-Butoxy-1-(2-hydroxypropyl)-4,5-dimethylimidazole-2-thione (13a): (chromatographic separation,
SiO2, CH2Cl2/EtOAc 5:1); 209 mg (81%). Pale yellow oil. [α]
20
D = +1.3 (c 0.77, CHCl3).
1H-NMR (CDCl3):
δ = 4.29–4.34 (m, 2H, OCH2, Bu), 4.18–4.23 (m, 1H, CHCH3), 4.03 (dd, J = 8.7, 14.4 Hz, 1H, NCH2),
3.97 (dd, J = 3.2, 14.4 Hz, 1H, NCH2), 3.28 (br.s, 1H, OH), 2.08, 2.12 (2s, 3H each, 2Me), 1.73–1.77 (m,
2H, Bu), 1.46–1.53 (m, 2H, Bu), 1.25 (d, J = 6.3 Hz, 3H, CHCH3), 0.96 (t, J = 7.4 Hz, 3H, CH3, Bu) ppm.
13C-NMR (CDCl3): δ = 156.2 (s, C=S), 118.5, 119.0 (2s, C(4), C(5)), 76.8 (t, OCH2, Bu), 67.3 (d, CHCH3),
51.3 (t, NCH2), 29.8 (t, CH2, Bu), 21.2 (q, CHCH3), 18.9 (t, CH2, Bu), 13.7 (q, CH3, Bu), 7.5, 9.1 (2q, 2Me)
ppm. IR (neat): ν 3353 (s), 3040–2874 (br, m), 1433 (m), 1409 (s), 1375 (m), 1347 (m), 1127 (m), 1072 (m),
943 (m) cm−1. ESI-MS (m/z): 281.1 (53, [M + Na]+), 259.1 (100, [M + H]+), 208.1 (42). C12H22N2O2S
(258.38): calcd. C 55.78, H 8.58, N 10.84, S 12.41; found: C 55.57, H 8.65, N 10.76, S 12.21.
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(R)-3-Butoxy-1-(2-hydroxy-1-phenylethyl)-4,5-dimethylimidazole-2-thione (13b): (chromatographic
separation, SiO2, CH2Cl2/EtOAc 5:1); 240 mg (75%). Yellow oil. [α]
20
D = −10.8 (c 0.73, CHCl3).
1H-NMR (CDCl3): δ = 7.24–7.30, 7.32–7.35 (2m, 3H, 2H, Ph), 6.26 (m, 1H, CHPh), 4.60–4.65 (m, 1H,
CH2OH), 4.34–4.42 (m, 3H, OCH2(Bu) (2H), CH2OH (1H)), 3.09 (br.s, 1H, OH), 2.09 (s, 3H, Me),
1.79–1.84 (m, 2H, Bu), 1.72 (s, 3H, Me), 1.52–1.58 (m, 2H, Bu), 1.00 (t, J = 7.4 Hz, 3H, CH3, Bu) ppm.
13C-NMR (CDCl3): δ = 157.4 (s, C=S), 136.7 (s, Ph), 126.9, 127.8, 128.7 (3d, 5CH, Ph), 118.8, 120.1 (2s,
C(4), C(5)), 76.8 (t, OCH2, Bu), 62.8 (t, CH2OH), 60.9 (d, CHPh), 29.9 (t, CH2, Bu), 19.0 (t, CH2, Bu), 13.8
(q, CH3, Bu), 7.4, 9.9 (2q, 2Me) ppm. IR (neat): ν 3347 (s), 3016–2874 (br, s), 1407 (s), 1333 (m), 1156 (m),
1060 (m), 1031 (m) cm–1. ESI-MS (m/z): 343.1 (54, [M + Na]+), 321.2 (100, [M + H]+), 270.1 (45). HRMS
(ESI-TOF): calcd for C17H25N2O2S: 321.1637; found: 321.1640.
(R)-3-Butoxy-4,5-dimethyl-1-[1-(methoxycarbonyl)ethyl]imidazole-2-thione (13c): (chromatographic
separation, SiO2, CH2Cl2/EtOAc 95:5); 236 mg (83%). Yellow oil. [α]
20
D = −45.4 (c 0.20, CHCl3).
1H-NMR (CDCl3): δ = 6.03 (d, J = 7.4 Hz, 1H, CHCH3), 4.31–4.39 (m, 2H, OCH2, Bu), 3.74 (s, 3H,
OCH3), 2.02, 2.12 (2s, 3H each, 2Me), 1.75–1.80 (m, 2H, Bu), 1.62 (d, J = 7.4 Hz, 3H, CHCH3), 1.49–1.55
(m, 2H, Bu), 0.98 (t, J = 7.4 Hz, 3H, CH3, Bu) ppm. 13C-NMR (CDCl3): δ = 170.8 (s, C=O), 157.6 (s,
C=S), 117.4, 119.8 (2s, C(4), C(5)), 76.7 (t, OCH2, Bu), 53.2 (d, CHCH3), 52.6 (q, OCH3), 29.9 (t, CH2, Bu),
19.0 (t, CH2, Bu), 16.0 (q, CHCH3), 13.8 (q, CH3, Bu), 7.4, 9.8 (2q, 2Me) ppm. IR (neat): ν 2932–2872 (m),
1743 (vs, C=O), 1407 (s), 1344 (m), 1224 (s), 1183 (s), 1109 (m), 1066 (s), 963 (m) cm−1. ESI-MS (m/z):
287.3 (100, [M + H]+). C13H22N2O3S (286.39): calcd. C 54.52, H 7.74, N, 9.78, S 11.19; found: C 54.58, H
7.79, N 9.77, S 11.18.
(R)-3-Butoxy-4,5-dimethyl-1-[(N-phenylethyl)acetamido]imidazole-2-thione (13d): (chromatographic
separation, SiO2, CH2Cl2/EtOAc 4:1); 238 mg (66%). Pale orange solid. M.p. 118–119 ◦C. [α]20D = +2.7
(c 1.89, CHCl3). 1H-NMR (CDCl3): δ = 7.71 (br.d, J ≈ 8.1 Hz, 1H, NH), 7.20–7.23, 7.25–7.30 (2m, 1H, 4H,
Ph), 5.00 (pseudo-p, J ≈ 7.1 Hz, 1H, CH(Ph)CH3), 4.65, 4.70 (AB system, J = 14.9 Hz, 2H, NCH2), 4.35 (dt,
J ≈ 6.6, 8.1 Hz, 1H, OCH2, Bu), 4.28 (dt, J ≈ 6.6, 8.1 Hz, 1H, OCH2, Bu), 2.11, 2.13 (2s, 3H each, 2Me),
1.76–1.81 (m, 2H, Bu), 1.50–1.56 (m, 2H, Bu), 1.43 (d, J = 7.0 Hz, 3H, CH(Ph)CH3), 0.99 (t, J = 7.4 Hz, 3H,
CH3, Bu) ppm. 13C-NMR (CDCl3): δ = 166.2 (s, C=O), 156.3 (s, C=S), 143.1 (s, Ph), 125.8, 127.0, 128.4
(3d, 5CH, Ph), 118.5, 119.5 (2s, C(4), C(5)), 76.9 (t, OCH2, Bu), 49.3 (d, CH(Ph)CH3), 48.6 (t, NCH2), 29.8
(t, CH2, Bu), 22.5 (q, CH(Ph)CH3), 18.9 (t, CH2, Bu), 13.7 (q, CH3, Bu), 7.4, 9.1 (2q, 2Me) ppm. IR (neat):
ν 3282 (m), 2956–2871 (br, m), 1662 (vs, C=O), 1549 (s), 1407 (s), 1372 (m), 1247 (m), 1003 (m) cm−1.
ESI-MS (m/z): 384.2 (100, [M + Na]+), 362.2 (21, [M + H]+), 311.1 (48), 241.1 (69). C19H27N3O2S (361.50):
calcd. C 63.13, H 7.53, N 11.62, S 8.87; found: C 63.04, H 7.80, N 11.70, S 8.76.
(S)-3-Benzyloxy-4,5-dimethyl-1-(1-phenylethyl)imidazole-2-thione (15a): Yield: 275 mg (81%). Pale
yellow crystals. M.p. 102–104 ◦C (petroleum ether/CH2Cl2). [α]20D = +110.5 (c 0.32, CHCl3). 1H-NMR
(CDCl3): δ = 7.58–7.53 (m, 2H), 7.43–7.40 (m, 3H), 7.37–7.34 (m, 2H), 7.30–7.26 (m, 3H), 6.80 (q, J = 7.3
Hz, 1H), 5.58, 5.45 (AB system, J = 10.0 Hz, 2H, OCH2), 1.83 (d, J = 7.3 Hz, 3H), 1.78, 1.63 (2s, 6H, 2Me)
ppm. 13C-NMR (CDCl3): δ = 157.3 (s, C=S), 126.4, 127.4, 128.5, 128.6, 129.3, 130.4 (6d, 10CH), 117.5,
120.7 134.0, 139 (4s), 77.9 (t, OCH2), 53.4 (d, CH), 7.2, 10.2, 17.3 (3q, 3Me) ppm. IR (neat): ν 2971 (m),
2924 (m), 1449 (m), 1403 (s), 1375 (m), 1332 (s), 1299 (m), 1151 (m), 1025 (m), 956 (m), 909 (m), 747 (s),
697 (vs) cm−1. HRMS (ESI-TOF) calcd for C20H23N2OS: 339.1531; found: 339.1535.
(S)-4,5-Dimethyl-3-pentyloxy-1-(1-phenylethyl)imidazole-2-thione (15b): Yield: 245 mg (77%). Pale
yellow crystals. M.p. 70–73 ◦C (petroleum ether/CH2Cl2). [α]20D = +125.9 (c 0.40, CHCl3). 1H-NMR
(CDCl3): δ = 7.28–7.39 (m, 5H), 6.76 (q, J = 7.3 Hz, 1H), 4.43–4.46 (pseudo q, J = 7.2 Hz, 1H, OCH2),
4.37–4.40 (pseudo q, J = 7.2 Hz, 1H, OCH2), 2.09 (s, 3H, Me), 1.83–1.88 (m, 2H, CH2), 1.80 (d, J = 7.3 Hz,
3H), 1.68 (s, 3H, Me), 1.49–1.53 (m, 2H, CH2), 1.41–1.45 (m, 2H, CH2), 0.96 (t, J = 7.3 Hz, 3H, CH3) ppm.
13C-NMR (CDCl3): δ = 157.5 (C=S), 126.5, 127.3, 128.5 (3d, 5CH), 117.8, 119.9, 139.9 (3s), 76.9 (t, OCH2),
53.4 (d, CH), 22.5, 27.7, 27.9 (3t, 3CH2), 7.3, 10.1, 13.9, 16.8 (4q, 4Me) ppm. IR (neat): ν 2954 (m), 2927
(m), 1450 (m), 1410 (s), 1334 (s), 1299 (s), 1157 (m), 1027 (m), 1001 (s), 998 (m), 876 (m), 700 (vs), 687 (s)
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cm−1. C18H26N2OS (318.48): calcd. C 67.88, H 8.23, N 8.80, S 10.07; found: C 67.61, H 8.28, N 8.70,
S 10.06.
(S)-3-Benzyloxy-4,5-diphenyl-1-(1-phenylethyl)imidazole-2-thione (15c): Yield: 305 mg (66%). Pale
yellow oil. [α]20D = +188.5 (c 0.40, CHCl3).
1H-NMR (CDCl3): δ = 7.30–7.32 (m, 2H), 7.20–7.25 (m, 10H),
7.14–7.18 (m, 2H), 7.05–7.12 (m, 6H), 6.75 (br.s, 1H, CH3-CH), 6.67 (br.s, 2H), 5.30, 5.32 (AB system, J =
12.5 Hz, 2H, OCH2), 1.62 (d, J = 6.5 Hz, 3H, CH3-CH) ppm. 13C-NMR (CDCl3): δ = 158.4 (s, C=S),
124.1, 125.9, 126.2, 128.6, 129.8, 132.9 (6s), 126.9, 127.3, 127.9, 128.0, 128.1, 128.2, 128.3, 128.9, 129.1, 129.4,
130.6, 132.0 (12d, 20CH), 77.7 (t, OCH2), 54.6 (d, CH), 17.5 (q, CH3) ppm. IR (neat): ν 3032 (m), 2927
(m), 1496 (m), 1446 (m), 1395 (s), 1325 (m), 1316s, 1215 (m), 1187 (m), 1073 (m), 907 (m), 730 (s), 695 (vs)
cm−1. HRMS (ESI-TOF): calcd for C30H27N2O: 463.1844; found: 463.1849.
(S)-3-Pentyloxy-4,5-diphenyl-1-(1-phenylethyl)imidazole-2-thione (15d): Yield: 350 mg (79%). Beige
crystals. M.p. 78–81 ◦C (petroleum ether/CH2Cl2). [α]20D = +130.1 (c 0.30, CHCl3). 1H-NMR (CDCl3):
δ = 7.20–7.25 (m, 9H), 7.06–7.09 (m, 4H), 6.67–6.73 (m, 3H, 2CHarom, CH-CH3), 4.31 (pseudo q, J = 6.8
Hz, 1H, OCH2), 4.14 (pseudo q, J = 6.8 Hz, 1H, OCH2), 1.63–1.66 (m, 2H, CH2), 1.59 (d, J = 6.8 Hz, 3H,
CH3-CH), 1.24–1.27 (m, 2H, CH2), 1.19–1.23 (m, 2H, CH2), 0.83 (t, J = 7.3 Hz, 3H, CH3) ppm. 13C-NMR
(CDCl3): δ = 158.6 (s, C=S), 126.9, 127.2, 127.9, 128.1, 128.2, 128.3, 128.9, 129.3, 132.0 (9d, 15CH), 124.4,
125.2, 126.0, 140.3 (4s), 76.9 (t, OCH2), 54.7 (d, CH), 22.2, 27.4, 27.8 (3t, 3CH2), 13.9, 17.5 (2q, 2CH3) ppm.
IR (neat): ν 2968 (m), 2953 (m), 1448 (m), 1392 (s), 1321 (s), 1187 (m), 1026 (m), 1002 (m), 963 (m), 702
(vs), 695 (vs) cm−1. C28H30N2OS (442.62): C 75.98; H 6.83; N 6.33; S 7.24. Found: C 75.78; H 6.88; N
6.58; S 7.50.
Supplementary Materials: Copies of 1H-NMR and 13C-NMR spectra of all new compounds are available online.
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